Ancrod infusion for anticoagulation during and after ptca in a patient with heparin-induced thrombocytopenia
- 1 July 1994
- journal article
- case report
- Published by Wiley in Catheterization and Cardiovascular Diagnosis
- Vol. 32 (3) , 286-287
- https://doi.org/10.1002/ccd.1810320320
Abstract
Ancrod is a rapid-acting defibrinogenating agent derived from the venom of the Malayan pit viper which has been used successfully as an alternative to heparin sulfate for anticoagulation during peripheral vascular procedures and coronary artery bypass surgery. We describe the first use of ancrod for anticoagulation before and during percutaneous transluminal coronary angioplasty (PTCA) in a patient with heparin-associated thrombocytopenia.Keywords
This publication has 8 references indexed in Scilit:
- Ancrod versus heparin for anticoagulation during vascular surgical proceduresJournal of Vascular Surgery, 1993
- A novel α-type fibrinogenase from Agkistrodon rhodostoma snake venomBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992
- Amino acid sequence determination of Ancrod, the thrombin‐like α‐fibrinogenase from the venom of Akistrodon rhodostomaFEBS Letters, 1992
- Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia [see comments]Blood, 1991
- Ancrod Causes Rapid Thrombolysis in Patients with Acute StrokeThe Lancet Healthy Longevity, 1990
- Ancrod (Arvin®) as an Alternative to Heparin Anticoagulation for Cardiopulmonary BypassAnesthesiology, 1989
- Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosisThe Annals of Thoracic Surgery, 1989
- Ancrod: A practical alternative to heparinJournal of Vascular Surgery, 1988